Immune Oncology Systems (IOS) is advancing a novel intratumoral drug delivery platform designed to enhance local tumor control while stimulating systemic anti-cancer immune responses.
The new paradigm of intraoperative immune activation and tumor decapitation.
Learn More
Sustained drug action combined with systemic immunotherapy (Abscopal effect).
Learn MoreAdvancing a robust clinical development strategy
| Program | Indication | Stage |
|---|---|---|
| IOS-101 | Resectable Pancreatic Cancer | Pre-IND |
| IOS-102 | Metastatic Pancreatic Cancer | IND Planning |
| IOS-201 | Solid Tumor Expansion Program | Discovery |
Major Breakthrough in Gynecological Oncology! Academician Baofa Yu Announces New Non-I...
Read More →On August 8-10, the 10th China Translational Medicine Conference and China Precision Medicine Con...
Read More →From June 18th to 20th, 2025, Stockholm, Sweden, hosted the annual grand event of the oncology fi...
Read More →Diagnosed with Stage 4 Prostate Cancer with bone metastases, Mark Harris found hope with our Immune Slow Release Therapy. Within months, his metastatic lesions disappeared. Years later, he trusted our platform again to treat his wife's lung cancer when conventional chemotherapy failed. A true testament to the power of precision intratumoral immunotherapy.
We are actively seeking strategic collaborations to accelerate our development programs.
